ChromaDex Corporation (CDXC) ニュース

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+

One of the most robust forms of intellectual property protection, a composition of matter patent grants ChromaDex exclusive rights to the...

ChromaDex Corporation Reports Second Quarter 2024 Financial Results

Total net sales of $22.7 million, up 12% year-over-year, gross margin of 60.2%, lower operating expenses, resulting in approximately breakeven...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

ChromaDex to Present at Canaccord Genuity’s 44th Annual Growth Conference

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today...

Form 3 - Initial statement of beneficial ownership of securities

ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced...

ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs)

Results from the at-home test kit are available to HCPs and their patients through 1health ChromaDex Corp...

ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces...

Form 8-K - Current report

ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August

U.S. FDA-registered 503B outsourcing facility, Wells Pharma of Houston, will compound and distribute Niagen (nicotinamide riboside chloride) IV...